A Study to Observe Pure Red Cell Aplasia (PRCA) Occurrence in Patients with Chronic Kidney Disease Who Used Hema-Plus (Recombinant Human Erythropoietin Alfa) at Ramathibodi Hospital
Phase 4
Completed
- Conditions
- -Pure Red Cell Aplasia (PRCA)
- Registration Number
- TCTR20170807003
- Lead Sponsor
- Apexcela Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Each patient included in the review must meet all of the following criteria to be in this study:
1.Presented with chronic kidney disease (CKD).
2.History of receiving Hema-Plus for at least 12 months during the study period.
Exclusion Criteria
Patients who met inclusion criteria but their medical records are not available for access.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method